Journal
JOURNAL OF EXTRACELLULAR VESICLES
Volume 10, Issue 4, Pages -Publisher
WILEY
DOI: 10.1002/jev2.12063
Keywords
high-resolution mass spectrometry (HRMS); melanoma cell-derived exosomes (MTEX); proteomics; small extracellular vesicles (sEV); tumour-derived exosomes (TEX)
Categories
Funding
- Narodowym Centrum Nauki [2016/22/M/NZ5/00667]
- US National Institutes of Health [R01-CA168628, U01-DE029759]
Ask authors/readers for more resources
This study demonstrates that molecular profiling of sEV isolated from plasma of cancer patients can distinguish tumor-derived sEV from non-malignant cell-derived sEV and identify potential prognostic biomarkers for melanoma.
Molecular profiling of small extracellular vesicles (sEV) isolated from plasma of cancer patients emerges as promising strategy for biomarkers discovery. We investigated the proteomic profiles of sEV immunoselected using anti-CSPG4 antibodies from 15 melanoma patients' plasma. The proteomes of sEV separated into melanoma cell-derived (MTEX) and non-malignant cell-derived (NMTEX) were compared using high-resolution mass spectrometry. Paired analysis identified the MTEX-associated profile of 16 proteins that discriminated MTEX from NNIECIA. We also identified the MTEX profile that discriminated between seven patients with no evidence of melanoma (NED) after therapy and eight with progressive disease (PD). Among 75 MTEX proteins overexpressed in PD patients, PDCD6IP (ALIX) had the highest discriminating value, while CNTN1 (contactin-1) was upregulated only in MTEX of NED patients. This is the first report documenting that proteomes of tumour-derived sEV in patients' plasma discriminate cancer from non-cancer and identify proteins with potential to serve as prognostic biomarkers in melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available